First-in-human drug study for advanced cancers and lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 1 trial tests BPI-371153, a new treatment, in people with advanced solid tumors or relapsed or refractory lymphoma whose cancer has returned or progressed after standard care. The goal is to find a safe dose and learn whether it can shrink tumors or help control disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be age 18 or older (and in this trial’s planned dose groups, up to age 65 for one part).
- Your cancer should be advanced (spread or locally advanced) or lymphoma that came back, and it must have progressed or you couldn’t tolerate or choose standard treatment (or none exists).
- Your body function score (ECOG) should be 0 or 1, meaning you can do most daily activities.
- You need at least one measurable tumor spot for tracking (with specific scan rules depending on cancer type).
- Your organs must work well enough for study medicines (blood counts, liver, kidneys, etc.).
- You cannot have recent immune checkpoint treatment (PD-1/PD-L1/PD-L2) before starting—timing rules are stricter for the expansion group.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early study tests a new medicine (BPI-460372) in adults with advanced solid cancers that have come back or can’t be treated with standard options. It may help by targeting specific cancer changes in certain tumors, and doctors will also learn the safest dose.
This Phase 1 trial tests LB1410, a new cancer treatment, to see if it is safe and may work for people with advanced cancers. It focuses on specific cancer types and requires certain prior treatments and lab test results.
This study tests a new drug, ILB-3101, for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and how well it works.
This trial tests a new drug called LPM6690176 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and how it affects the body.
This trial tests a new drug called PLB-002 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective, especially for cancers that show a specific marker called CLDN6.
This trial tests a new drug called IBI363 for people with advanced solid tumors, focusing on lung cancer and melanoma. It aims to see if the drug is safe and effective, especially for those whose previous treatments have stopped working.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.